Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
My previous session
Most popular
  Report  
Delayed Quote. Delayed Nasdaq - 03/20 04:00:00 pm
146.16 USD   -0.53%
02/25DEXCOM : Announces Upcoming Conference Presentation
BU
02/22DEXCOM : G6® CGM System Receives Health Canada Approval
AQ
02/21DEXCOM : 4Q Earnings Snapshot
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/14/2019 03/15/2019 03/18/2019 03/19/2019 03/20/2019 Date
146.85(c) 151(c) 146.22(c) 146.94(c) 146.16(c) Last
1 349 535 3 072 461 1 503 766 1 492 001 858 661 Volume
-0.41% +2.83% -3.17% +0.49% -0.53% Change
More quotes
Financials (USD)
Sales 2019 1 231 M
EBIT 2019 62,4 M
Net income 2019 24,3 M
Finance 2019 373 M
Yield 2019 -
Sales 2020 1 457 M
EBIT 2020 111 M
Net income 2020 83,6 M
Finance 2020 372 M
Yield 2020 -
P/E ratio 2019 609,00
P/E ratio 2020 172,89
EV / Sales2019 10,4x
EV / Sales2020 8,78x
Capitalization 13 155 M
More Financials
Company
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4... 
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on DEXCOM, INC.
02/25DEXCOM : Announces Upcoming Conference Presentation
BU
02/23NOVO NORDISK : Abbott and Novo Nordisk to offer integrated solution for diabetes
AQ
02/22DEXCOM : G6® CGM System Receives Health Canada Approval
AQ
02/21DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/21DEXCOM : 4Q Earnings Snapshot
AQ
02/21DEXCOM INC : Results of Operations and Financial Condition, Costs Associated wit..
AQ
02/21DEXCOM : Reports Fourth Quarter and Fiscal Year 2018 Financial Results
BU
01/25Digital Diabetes Management Market Value is expected to reach 20 Billion By 2..
AQ
01/24DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time
BU
01/07DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Sector news : Medical Equipment, Supplies & Distribution - NEC
08:33aLEONARDO DEL VECCHIO : EssilorLuxottica's Sagnieres hits back at attack from Del..
RE
06:13aEssilorLuxottica shares slump on new Franco-Italian board ructions
RE
03:41aESSILORLUXOTTICA : Chairman Reveals Governance Rift at Merged Company -Le Figaro
DJ
03:24aESSILORLUXOTTICA : infighting flares with new accusations
RE
03/18ESSILORLUXOTTICA : hires headhunter to search for CEO - sources
RE
More sector news : Medical Equipment, Supplies & Distribution - NEC
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 162 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jeffrey C. Moy Senior Vice President-Operations
Quentin Blackford Chief Financial Officer
Jacob Leach Senior Vice President-Research & Development
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.22.00%13 155
MEDTRONIC PLC0.84%123 010
BAXTER INTERNATIONAL INC.17.26%39 558
ZIMMER BIOMET HOLDINGS22.86%26 051
HOYA CORPORATION13.32%25 258
TERUMO CORP14.22%23 852